ArticleEJHaem2026
Molecular Characterization of Mobilized Apheresis Hematopoietic Progenitor Cells Designated for Autologous Stem Cell Transplantation in Multiple Myeloma.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Multiple myeloma is the second most common malignancy of the lymphoid system and accounts for about 2% of cancer deaths. Treatment generally consists of chemotherapy and autologous stem cell transplantation. Clinical trial results are equivocal as to whether autologous stem cell transplantation in the treatment of multiple myeloma prolongs overall survival. One possible etiology for this conundrum could be that the transplanted autologous stem cells may also contain residual tumor cells/tumor stem cells. Methods: Residual autologous stem cells from patients undergoing stem cell transplantation were examined for cells containing monoclonal immunoglobulins and clonotypic DNA detected in diagnostic bone marrow to determine if malignant myeloma cells may have been transplanted along with hematopoietic stem cells. Results: In all eight cases of autologous stem cell transplants examined from multiple myeloma patients, the infused cells included cells containing monoclonal immunoglobulins of the same type as were noted in patients' sera at the time of diagnosis. This was not seen in allogeneic cells from donors without cancer. In all four cases in which a dominant clone was identified by molecular analysis in the diagnostic bone marrow, the same clone was detectable in the autologous stem cells. Conclusions: We posit that lack of prolongation of overall survival with autologous stem cell transplantation in multiple myeloma is in part due to infusion of cells containing tumor cells that repopulate the recipient. This finding may warrant novel collection and processing strategies to mitigate the infusion of malignant cells. Until such methods become available, the use of autologous stem cell transplantation should be considered in the context of the conundrum reported here. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.